ABBV vs. SKHY: AbbVie vs. SK hynix Stock Comparison

Company Profile

AbbVie (ABBV) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas SK hynix (SKHY) belongs to Information Technology (Semiconductors & Semiconductor Equipment) — their GICS classifications point to very different parts of the market.

AbbVie (ABBV) has been public since January 2, 2013 with a meaningfully longer listed history, while SK hynix (SKHY) only listed on July 10, 2026 — long-window metrics on the SKHY side should be interpreted with caution.

AbbVie (ABBV) trades as ordinary local shares, while SK hynix (SKHY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

SK hynix (SKHY) has a highly aggressive beta of 5.36, indicating much higher sensitivity to broad-market moves, while AbbVie (ABBV) is defensive at 0.21 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Both ABBV and SKHY need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: SK hynix (SKHY) earns 92.54% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

SK hynix (SKHY) at 70.27% keeps the most of each sales dollar — above its industry’s net margin range — and AbbVie (ABBV) at 15.67% also retains a top-quartile share.

SK hynix (SKHY) at 79.66% shows unusually strong operating efficiency — above its industry’s operating margin range — and AbbVie (ABBV) at 39.59% also operates in the top quartile.

Profitability Metrics

Growth

SK hynix (SKHY) at 46.76% sits in the top revenue growth quartile, while AbbVie (ABBV) at 8.57% is closer to the peer norm — faster top-line expansion for SKHY.

SK hynix (SKHY) at 112.46% sits in the top EPS growth quartile, while AbbVie (ABBV) at -0.84% is closer to the peer norm — faster per-share earnings growth for SKHY.

Growth Metrics

Financial Strength

SK hynix (SKHY) at 26.88 carries current ratio above its industry’s typical mid-range, while AbbVie (ABBV) at 0.87 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Only one side’s leverage can be read here: SK hynix (SKHY) carries debt-to-equity ratio of 0.05 against its industry range, while AbbVie (ABBV) reports no figure this period.

Financial Strength Metrics

Dividends

Both AbbVie (ABBV) at 2.40% and SK hynix (SKHY) at 2,118.64% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; SK hynix (SKHY) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

SK hynix (SKHY) at 8.12 sits in the cheaper P/E ratio quartile, while AbbVie (ABBV) at 50.05 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.

SK hynix (SKHY) at 0.00 sits in the cheaper P/S ratio quartile while AbbVie (ABBV) at 7.80 prices around its industry’s middle — SKHY costs less per dollar of sales, though read it alongside growth and margins.

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile SK hynix (SKHY) reports 3.95, ranking against industry peers normally.

Valuation Metrics